Adjunctive behavioural treatment in adolescents and young adults with juvenile myoclonic epilepsy

نویسنده

  • Žarko Martinovic
چکیده

This study was designed to assess the effects of behavioural treatment on seizure recurrence, on seizure precipitants, and on associated psychiatric disturbances in 22 adolescents and young adults (age range 16-32 years, male : female ratio 10 : 12) with juvenile myoclonic epilepsy (JME) who showed seizure relapses despite rational AED therapy. The neurological assessment and a systematic search for seizure precipitants preceded to the use of psychiatric interviews and rating scales for anxiety and depression. After a structured counselling aiming at the elimination of seizure precipitants, the patients were assigned to one of two treatment modalities (an antistress programme or an individual cognitive behavioural therapy). Structured counselling was associated with complete seizure control in eight patients. In other 14 subjects with uncontrolled seizures, the psychotherapeutic treatment had two types of effects. First, the patients' fears and other unadapted responses, in the form of anxiety states and/or insomnia were significantly decreased during behavioural treatment. Second, a significantly lower rate of relapses occurred during behavioural treatment than during the baseline period. The results encourage the use of adjunctive behavioural treatment methods in decreasing seizure frequency, seizure precipitants and some types of comorbid psychopathology in patients with JME.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Update on rufinamide in childhood epilepsy

Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007. In January 2009, rufinamide was a...

متن کامل

Lacosamide treatment of juvenile myoclonic epilepsy

Juvenile myoclonic epilepsy is the most common form of idiopathic generalized epilepsy with onset at puberty or late teenage years. About 80-90% of patients with juvenile myoclonic epilepsy respond to appropriate antiepileptic treatment and achieve seizure freedom, and about 15% of patients become intractable. Valproic acid, levetiracetam, lamotrigine, topiramate and zonisamide are used as firs...

متن کامل

Levetiracetam for the treatment of epilepsy in children

(DGN) explicitly recommend the anticonvulsive agent levetiracetam – in addition to lamotrigine – as the agent of first choice for initial treatment of focal seizures with or without secondary generalisation from the age of 16 years onward. Furthermore, levetiracetam is indicated for additional treatment of myoclonic seizures in adults and adolescents from the age of 12 years onward with juvenil...

متن کامل

Levetiracetam in the treatment of childhood epilepsy

Epilepsy is a common pediatric neurologic disorder that is difficult to manage in a substantial portion of children. Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children: for refractory partial seizures in epilepsy patients >/=4 years old, for myoclonic seizures in juve...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Seizure

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2001